Current concepts in the pharmacotherapy of paraphilias

Drugs

Volumn 71, Issue 6, 2011, Pages 771-790

  Garcia, Frederico D ^a   Thibaut, Florence ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b HÔPITAL CHARLES NICOLLE   (France)

Author keywords

Clomipramine, therapeutic use; Cyproterone, therapeutic use; Escitalopram, therapeutic use; Fluoxetine, therapeutic use; Fluvoxamine, therapeutic use; Gonadotropin releasing hormone stimulants, therapeutic use; Imipramine, therapeutic use; Leuprorelin, therapeutic use; Medroxyprogesterone, therapeutic use; Nefazodone, therapeutic use; Paraphilias, diagnosis; Paraphilias, epidemiology; Paraphilias, treatment; Paroxetine,therapeutic use; Serotonin uptake inhibitors, therapeutic use; Sertraline, therapeutic use; Triptorelin, therapeutic use

Indexed keywords

ANTIANDROGEN; BUSPIRONE; CLOMIPRAMINE; CYPROTERONE; DESIPRAMINE; ESCITALOPRAM; ESTROGEN; ETHINYLESTRADIOL; FLUOXETINE; FLUTAMIDE; FLUVOXAMINE; GONADORELIN AGONIST; IMIPRAMINE; LEUPRORELIN; LIVER ENZYME; LUTEINIZING HORMONE; MEDROXYPROGESTERONE; METHYLPHENIDATE; NEFAZODONE; PAROXETINE; PROLACTIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TESTOSTERONE; TRICYCLIC ANTIDEPRESSANT AGENT; TRIPTORELIN;

ADRENAL HYPERPLASIA; ADRENAL INSUFFICIENCY; ADRENAL SUPPRESSION; ANDROGEN DEFICIENCY; ANEMIA; ASTHENIA; BLOOD PRESSURE; BONE ATROPHY; BONE DEMINERALIZATION; BONE DENSITY; CLINICAL TRIAL (TOPIC); COMPULSION; COMPULSIVE MASTURBATION; CUSHING DISEASE; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; EJACULATION DISORDER; ERECTILE DYSFUNCTION; EXHIBITIONISM; FETISHISM; FRAGILITY FRACTURE; GALLSTONE; GLUCOSE TOLERANCE; GYNECOMASTIA; HAIR DISEASE; HAIR LOSS; HEART FAILURE; HIGH RISK PATIENT; HIP FRACTURE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERSEXUALITY; HYPERTENSION; HYPOANDROGENISM; HYPOPHYSIS DISEASE; IMPOTENCE; INJECTION SITE PAIN; INSOMNIA; KIDNEY DYSFUNCTION; LEG CRAMP; LETHARGY; LIVER TOXICITY; LUTEINIZING HORMONE RELEASE; MASTURBATION; MEDICAL ETHICS; MONOTHERAPY; NAUSEA; OBSESSIVE COMPULSIVE DISORDER; OSTEOPOROSIS; PATIENT COMPLIANCE; PEDOPHILIA; PRESCRIPTION; PREVALENCE; PSYCHIATRIC DIAGNOSIS; PSYCHOTHERAPY; RAPE; RECURRENT DISEASE; REVIEW; SADISM; SEBUM SECRETION; SEMEN ABNORMALITY; SEXUAL BEHAVIOR; SEXUAL CRIME; SEXUAL DEVIATION; SIDE EFFECT; SLEEP DISORDER; SPERMATOGENESIS; SUICIDE; TESTIS SIZE; THROMBOEMBOLISM; VIOLENCE; WEIGHT GAIN;

ANDROGEN ANTAGONISTS; ANTIDEPRESSIVE AGENTS; COMBINED MODALITY THERAPY; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; PARAPHILIAS; PSYCHOTHERAPY; TREATMENT OUTCOME;

EID: 79955000776     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11585490-000000000-00000     Document Type: Review

References (150)

1. Krafft-Ebbing R. Psychopathia sexualis. New York: Paperback Library, 1886/1965
2. American Psychiatric Association. Task Force on DSM-IV: diagnostic and statistical manual of mental disorders (DSM-IV-TR). 4th, reviewed ed. Washington, DC: American Psychiatric Association, 2000
3. Cohen LJ, Galynker II. Clinical features of pedophilia and implications for treatment. J Psychiatr Pract 2002 Sep; 8 (5): 276-89
4. Kutchinsky B. Pornography and its effects in Denmark and the United States. Comp Soc Res 1985; 8: 301-30
5. Advisory Board on Child Abuse and Neglect. Child abuse and neglect: critical first steps in response to a national emergency. Washington, DC: US Government Printing Office, 1990
6. Ministry of Supply and Services Canada. Report of the Committee on Sexual Offenses against Children and Youths: sexual offenses against children in Canada. Ottawa: Supply and Services Canada, 1984
7. Finkelhor D, Araji S. Explanations of pedophilia: a four factor model. J Sex Res 1986; 22: 145-61 (Pubitemid 16074891)
8. Rosler A, Witztum E. Treatment of men with paraphilia with a long-acting analogue of gonadotropin-releasing hormone. N Engl J Med 1998 Feb 12; 338 (7): 416-22 (Pubitemid 28135668)
9. Thibaut F, De La Barra F, Gordon H, et al. The World Federation of Societies of Biological Psychiatry (WFSBP): guidelines for the biological treatment of paraphilias. World J Biol Psychiatry 2010 Jun; 11 (4): 604-55
10. Garcia FD, Thibaut F. Sexual addictions. Am J Drug Alcohol Abuse 2010 Sep; 36 (5): 254-60
11. American Psychiatric Association. DSM-5 development, proposed revisions: sexual and gender identity disorders [online]. Available from URL: http://www.dsm5.org/ ProposedRevisions/Pages/SexualandGenderIdentityDis orders.aspx [Accessed 2010 Aug 17]
12. Paraphilias Subworkgroup DSM-5 development, proposed revisions: 302.2 Pedophilia [online]. Available from URL http://www.dsm5.org/ProposedRevisions/ Pages/propo sedrevision.aspx?rid=186# [Accessed 2010 Dec 3]
13. First MB. DSM-5 proposals for paraphilias: suggestions for reducing false positives related to use of behavioral manifestations. Arch Sex Behav 2010 Dec; 39 (6): 1239-44; author reply 1245-52
14. O'Donohue W.A critiqueofthe proposed DSM-V diagnosis of pedophilia. Arch Sex Behav 2010 Jun; 39(3) 587-90
15. Abel GG, Osborn C. The paraphilias: the extent and nature of sexually deviant and criminal behavior. Psychiatr Clin North Am 1992 Sep; 15 (3): 675-87
16. Fagan PJ, Wise TN, Schmidt Jr CW, et al. Pedophilia. JAMA 2002 Nov 20; 288 (19): 2458-65 (Pubitemid 35340542)
17. Hall RC. A profile of pedophilia: definition, characteristics of offenders, recidivism, treatment outcomes, and forensic issues. Mayo Clin Proc 2007 Apr; 82 (4): 457-71 (Pubitemid 46543471)
18. Tesson J, Cordier B, Thibaut F. Assessment of a new law for sex offenders implemented in France in 1998. Encephale. In press
19. Tournier PV. Agressions sexuelles: du depot de plainte a l'execution des peines. In: Tournier PV, editor. Agressions sexuelles: victimes et auteurs. Paris: L'Harmattan, 1998: 27-56
20. Home Office. Home Office statistical bulletin: statistics of mentally disordered offenders in England and Wales 1996. London: Home Office, 1997
21. Marshall P. The prevalence of convictions for sexual of-fending. 55th ed. London: Home Office Research and Statistics, 1997
22. Kafka MP, Hennen J. A DSM-IV Axis I comorbidity study of males (n =120) with paraphilias and paraphilia-related disorders. Sex Abuse 2002 Oct; 14 (4): 349-66
23. Langstrom N, Seto MC. Exhibitionistic and voyeuristic behavior in a Swedish national population survey. Arch Sex Behav 2006 Aug; 35 (4): 427-35 (Pubitemid 44450964)
24. Langstrom N, Zucker KJ. Transvestic fetishism in the general population: prevalence and correlates. J Sex Marital Ther 2005 Mar-Apr; 31 (2): 87-95
25. Oliveira Junior WM, Abdo CH. Unconventional sexual behaviors and their associations with physical, mental and sexual health parameters: a study in 18 large Brazilian cities. Rev Bras Psiquiatr 2010 Sep; 32 (3): 264-74
26. Marsh PJ, Odlaug BL, Thomarios N, et al. Paraphilias in adult psychiatric inpatients. Ann Clin Psychiatry 2010; 22 (2): 129-34
27. Blanchard R, Watson MS, Choy A, et al. Pedophiles: mental retardation, maternal age, and sexual orientation. Arch Sex Behav 1999 Apr; 28 (2): 111-27 (Pubitemid 29260585)
28. Bagley C, Wood M, Young L. Victim to abuser: mental health and behavioral sequels of child sexual abuse in a community survey of young adult males. Child Abuse Negl 1994 Aug; 18 (8): 683-97 (Pubitemid 24243555)
29. Abel GG, Harlow N. The Abel and Harlow child moles-tation prevention study. In: Abel GG, Harlow N, editors. The stop child molestation book. Philadelphia, PA: Xlibris, 2001
30. Murray JB. Psychological profile of pedophiles and child molesters. J Psychol 2000 Mar; 134 (2): 211-24
31. Dickey R, Nussbaum D, Chevolleau K, et al. Age as a differential characteristic of rapists, pedophiles, and sexual sadists. J Sex Marital Ther 2002 May-Jun; 28 (3): 211-8 (Pubitemid 34438388)
32. Abel GG, Becker JV, Cunningham-Rathner J, et al. Mul-tiple paraphilic diagnoses among sex offenders. Bull Am Acad Psychiatry Law 1988; 16 (2): 153-68
33. Raymond NC, Coleman E, Ohlerking F, et al. Psychiatric comorbidity in pedophilic sex offenders. Am J Psychiatry 1999 May; 156 (5): 786-8 (Pubitemid 29220084)
34. Bradford JM, Boulet J, Pawlak A. The paraphilias: a multiplicity of deviant behaviours. Can J Psychiatry 1992 Mar; 37 (2): 104-8
35. Galli V, McElroy SL, Soutullo CA, et al. The psychiatric diagnoses of twenty-two adolescents who have sexually molested other children. Compr Psychiatry 1999 Mar-Apr; 40 (2): 85-8 (Pubitemid 29108617)
36. Maletzky BM. Factors associated with success and failure in the behavioral and cognitive treatment of sexual offenders. Ann Sex Res 1994; 6: 241-58
37. McElroy SL, Soutullo CA, Taylor Jr P, et al. Psychiatric features of 36 men convicted of sexual offenses. J Clin Psychiatry 1999 Jun; 60 (6): 414-20; quiz 421-2 (Pubitemid 29289734)
38. Raymond NC, Coleman E, Miner MH. Psychiatric co-morbidity and compulsive/impulsive traits in compulsive sexual behavior. Compr Psychiatry 2003 Sep-Oct; 44 (5): 370-80 (Pubitemid 37151812)
39. Craig LA, Browne KD, Stringer I, et al. Sexual reconvic-tion rates in the United Kingdom and actuarial risk estimates. Child Abuse Negl 2008 Jan; 32 (1): 121-38
40. Hanson RK, Morton-Bourgon KE. The characteristics of persistent sexual offenders: a meta-analysis of recidivism studies. J Consult Clin Psychol 2005 Dec; 73 (6): 1154-63 (Pubitemid 43161113)
41. Hanson RK, Morton KE, Harris AJ. Sexual offender re-cidivism risk: what we know and what we need to know. Ann N Y Acad Sci 2003 Jun; 989: 154-66; discussion 236-46 (Pubitemid 36808402)
42. Harris AJR, Hanson RK. La recidive sexuelle: d'une simplicite trompeuse. Ottawa, Canada: Securite publique et Protection civile Canada 2004. Available from URL: http://www.publicsafety.gc.ca/res/cor/rep/2004-03-se-off-fra.aspx [Accessed 2011 Apr 4]
43. Hanson RK, Thornton D. Static-99: Improving actuarial risk assessments for sex offenders (User Report No. 1999-02) [online]. Available from URL: http://www.courtdiagnostic. com/Static%2099-02.pdf [Accessed 2011 Apr 4]
44. Hanson RK. The development of a brief actuarial risk scale for sexual offense recidivism (User Report No. 1997-04). Ottawa: Public Works and Government Services Canada, 1997 [online]. Available from URL: http://www.defense forsvp.com/Resources/Hanson-Static-99/RRASOR.pdf [Accessed 2011 Apr 4]
45. Quinsey VL, Harris GT, Rice ME, et al. Violent offenders: appraising and managing risk. Washington, DC: American Psychological Association, 2006
46. Boer DP, Hart SD, Kropp PR, et al. Sexual Violence Risk-20: professional guidelines for assessing violence risk. Vancouver: Mental Health Law & Policy Institute, Simon Fraser University, 1997
47. Hare RD. Manual for the Psychopathy Checklist-Revised. Toronto: Multi Health Systems, 1991
48. Rettenberger M, Matthes A, Boer DP, et al. Prospective actuarial risk assessment: a comparison of five risk assessment instruments in different sexual offender subtypes. Int J Offender Ther Comp Criminol 2009 Apr; 54 (2): 169-86
49. Olver ME, Wong SCP. A comparison of static and dy-namic assessment of sexual offender risk and need in a treatment context. Crim Justice Behav 2011; 38 (2): 113-26
50. White P, Bradley C, Ferriter M, et al. Managements for people with disorders of sexual preference and for convicted sexual offenders. Cochrane Database Syst Rev 2000; (2): CD000251
51. Losel F, Schmucker M. The effectiviness of treatment for sexual offenders: a comprehensive meta-analysis. J Exp Criminol 2005; 1 (1): 117-46 (Pubitemid 41310192)
52. Hull EM, Muschamp JW, Sato S. Dopamine and ser-otonin: influences on male sexual behavior. Physiol Behav 2004 Nov 15; 83 (2): 291-307 (Pubitemid 39361571)
53. Verma S, Chhina GS, Mohan Kumar V, et al. Inhibition of male sexual behavior by serotonin application in the medial preoptic area. Physiol Behav 1989 Aug; 46 (2): 327-30 (Pubitemid 19244098)
54. Fernandez-Guasti A, Escalante AL, Ahlenius S, et al. Sti-mulation of 5-HT1A and 5-HT1B receptors in brain regions and its effects on male rat sexual behaviour. Eur J Pharmacol 1992 Jan 14; 210 (2): 121-9
55. Yells DP, Hendricks SE, Prendergast MA. Lesions of the nucleus paragigantocellularis: effects on mating behavior in male rats. Brain Res 1992 Nov 20; 596 (1-2): 73-9
56. Ahlenius S, Carlsson A, Hillegaart V, et al. Region-selec-tive activation of brain monoamine synthesis by sexual activity in the male rat. Eur J Pharmacol 1987 Nov 24; 144 (1): 77-82 (Pubitemid 18005056)
57. Albinsson A, Andersson G, Andersson K, et al. The effects of lesions in the mesencephalic raphe systems on male rat sexual behavior and locomotor activity. Behav Brain Res 1996 Oct; 80 (1-2): 57-63 (Pubitemid 26342031)
58. Kondo Y, Yamanouchi K. Potentiation of ejaculatory ac-tivity by median raphe nucleus lesions in male rats: effect of p-chlorophenylalanine. Endocr J 1997 Dec; 44 (6): 873-9 (Pubitemid 28071172)
59. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sex-ual function: a critical review. J Clin Psychopharmacol 1999 Feb; 19 (1): 67-85 (Pubitemid 29047334)
60. Waldinger MD, Berendsen HH, Blok BF, et al. Premature ejaculation and serotonergic antidepressants-induced delayed ejaculation: the involvement of the serotonergic system. Behav Brain Res 1998 May; 92 (2): 111-8 (Pubitemid 28223582)
61. Waldinger MD, Hengeveld MW, Zwinderman AH, et al. Effect of SSRI antidepressants on ejaculation: a double-blind, randomized, placebo-controlled study with fluox-etine, fluvoxamine, paroxetine, and sertraline. J Clin Psychopharmacol 1998 Aug; 18 (4): 274-81 (Pubitemid 28353869)
62. Waldinger MD, Olivier B. Selective serotonin reuptake in-hibitor-induced sexual dysfunction: clinical and research considerations. Int Clin Psychopharmacol 1998 Jul; 13 Suppl. 6: S27-33 (Pubitemid 28372349)
63. Bradford JM. The paraphilias, obsessive compulsive spec-trum disorder, and the treatment of sexually deviant behaviour. Psychiatr Q 1999 Fall; 70 (3): 209-19 (Pubitemid 29380353)
64. Goldner RD. Control of minor criminal sexual compul-sions with imipramine and amine oxidase inhibitors. Third World Congress of Psychiatry; 1961 Jun 10; Montreal (QC)
65. Coleman E. Sexual compulsivity: definition, etiology and treatment. J Chem Dep Treat 1987; 1: 189-204
66. Kafka MP, Coleman E. Serotonin and paraphilias: the convergence of mood, impulse and compulsive disorders. J Clin Psychopharmacol 1991 Jun; 11 (3): 223-4
67. Kruesi MJ, Fine S, Valladares L, et al. Paraphilias: a double-blind crossover comparison of clomipramine versus desi-pramine. Arch Sex Behav 1992 Dec; 21 (6): 587-93 (Pubitemid 23024475)
68. Wawrose FE, Sisto TM. Clomipramine and a case of ex-hibitionism [letter]. Am J Psychiatry 1992 Jun; 149 (6): 843
69. Torres AR, Cerqueira AT. Exhibitionism treated with clomipramine [letter]. Am J Psychiatry 1993 Aug; 150 (8): 1274
70. Casals-Ariet C, Cullen K. Exhibitionism treated with clo-mipramine. Am J Psychiatry 1993 Aug; 150 (8): 1273-4
71. Clayton AH. Fetishism and clomipramine. Am J Psychia-try 1993 Apr; 150 (4): 673-4
72. Adi Y, Ashcroft D, Browne K, et al. Clinical effectiveness and cost-consequences of selective serotonin reuptake inhibitors in the treatment of sex offenders. Health Technol Assess 2002; 6 (28): 1-66
73. Fedoroff JP. Buspirone hydrochloride in the treatment of transvestic fetishism. J Clin Psychiatry 1988 Oct; 49 (10): 408-9 (Pubitemid 18261497)
74. Bianchi MD. Fluoxetine treatment of exhibitionism. Am J Psychiatry 1990 Aug; 147 (8): 1089-90 (Pubitemid 20257528)
75. Lorefice LS. Fluoxetine treatment of a fetish [letter]. J Clin Psychiatry 1991 Jan; 52 (1): 41
76. Emmanuel NP, Lydiard RB, Ballenger JC. Fluoxetine treatment of voyeurism [letter]. Am J Psychiatry 1991 Jul; 148 (7): 950
77. Kafka MP. Successful antidepressant treatment of non-paraphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1991 Feb; 52 (2): 60-5
78. Perilstein RD, Lipper S, Friedman LJ. Three cases of paraphilias responsive to fluoxetine treatment. J Clin Psychiatry 1991 Apr; 52 (4): 169-70
79. Fedoroff JP. Buspirone hydrochloride in the treatment of an atypical paraphilia. Arch Sex Behav 1992 Aug; 21 (4): 401-6
80. Coleman E, Cesnik J, Moore AM, et al. An exploratory study of the role of psychotropic mediations in treatment of sexual offenders. J Offend Rehabil 1992; 18: 75-88
81. Stein DJ, Hollander E, Anthony DT, et al. Serotonergic medications for sexual obsessions, sexual addictions, and paraphilias. J Clin Psychiatry 1992 Aug; 53 (8): 267-71
82. Kafka MP, Prentky R. Fluoxetine treatment of non-paraphilic sexual addictions and paraphilias in men. J Clin Psychiatry 1992 Oct; 53 (10): 351-8
83. Kafka MP. Sertraline pharmacotherapy for paraphilias and paraphilia-related disorders: an open trial. Ann Clin Psychiatry 1994 Sep; 6 (3): 189-95
84. Zohar J, Kaplan Z, Benjamin J. Compulsive exhibitionism successfully treated with fluvoxamine: a controlled case study. J Clin Psychiatry 1994 Mar; 55 (3): 86-8
85. Fedoroff JP. Antiandrogens vs serotonergic medications in the treatment of sex offenders: a preliminary compliance study. Can J Hum Sexuality 1995; 4: 111-23
86. Bradford JM, Martindale JJ, Goldberg M, et al. Sertraline in the treatment of pedophilia: an open label study. New Research Program Abstracts, NR 441. APA Annual Meeting; 1996 May; Miami, FL
87. Bourgeois JA, Klein M. Risperidone and fluoxetine in the treatment of pedophilia with comorbid dysthymia. J Clin Psychopharmacol 1996 Jun; 16 (3): 257-8 (Pubitemid 26227928)
88. Greenberg DM, Bradford JM, Curry S,et al. A comparison of treatment of paraphilias with three serotonin reuptake inhibitors: a retrospective study. Bull Am Acad Psychiatry Law 1996; 24 (4): 525-32
89. Galli VB, Raute NJ, McConville BJ, et al. An adolescent male with multiple paraphilias successfully treated with fluox-etine. J Child Adolesc Psychopharmacol 1998; 8 (3): 195-7 (Pubitemid 28550710)
90. Abouesh A, Clayton A. Compulsive voyeurism and ex-hibitionism: a clinical response to paroxetine. Arch Sex Behav 1999 Feb; 28 (1): 23-30 (Pubitemid 29100829)
91. Aguierre B. Fluoxetine and compulsive sexual behaviour [letter]. J Am Acad Child Adolesc Psychiatry 1999; 38 (8): 943
92. Kafka MP, Hennen J. Psychostimulant augmentation dur-ing treatment with selective serotonin reuptake inhibitors in men with paraphilias and paraphilia-related disorders: a case series. J Clin Psychiatry 2000 Sep; 61 (9): 664-70
93. Coleman E, Gratzer T, Nesvacil L, et al. Nefazodone and the treatment of nonparaphilic compulsive sexual behavior: a retrospective study. J Clin Psychiatry 2000 Apr; 61 (4): 282-4 (Pubitemid 30305370)
94. Chow EW, Choy AL. Clinical characteristics and treat-ment response to SSRI in a female pedophile. Arch Sex Behav 2002 Apr; 31 (2): 211-5 (Pubitemid 38481267)
95. Phahaj SK. Escitalopram treatment of transvestic fetish-ism: case report. German J Psychiatry 2004; 7 (2): 20-1
96. Yang FW, Liang CS. Paraphilias in schizophrenia: differ-ential diagnosis and treatment with selective serotonin reuptake inhibitors. Prog Neuropsychopharmacol Biol Psychiatry 2010 Aug 16; 34 (6): 1126-7
97. Kafka MP, Prentky R. Fluoxetine treatment of non-para-philic sexual addictions and paraphilias in men. J Clin Psychiatry 1992; 53: 351-8
98. Bradford JM. The treatment of sexual deviations using a pharmacological approach. J Sex Res 2000; 37 (3): 248-57
99. Bradford JM, Fedoroff JP. Pharmacological treatment of the juvenile sex offender. In: Barbaree H, Marshall W, editors. The juvenile sex offender. 2nd ed. New York: Guildford Press; 2006: 358-82
100. Whittaker LH. Estrogens and psychosexual disorders. Med J Aust 1959; 2: 547-9
101. Bancroft J, Tennent G, Loucas K, et al. The control of deviant sexual behaviour by drugs. I. Behavioural changes following oestrogens and anti-androgens. Br J Psychiatry 1974 Sep; 125 (0): 310-5
102. Murray MA, Bancroft JH, Anderson DC, et al. Endocrine changes in male sexual deviants after treatment with anti-androgens, oestrogens or tranquillizers. J Endocrinol 1975 Nov; 67 (2): 179-88
103. Southren AL, Gordon GG, Vittek J, et al. Effect of pro-gestagens on androgen metabolism. In: Martini L, Motta M, editors. Androgens and antiandrogens. New York: Raven Press; 1977: 263-79
104. Gottesman HG, Schubert DS. Low-dose oral medroxy-progesterone acetate in the management of the para-philias. J Clin Psychiatry 1993 May; 54 (5): 182-8 (Pubitemid 23175819)
105. Money J. Discussion on hormonal inhibition of libido in male sex offenders. In: Michael RP, editor. Endocrinology and human behaviour. London: Oxford University Press, 1968: 169
106. Meyer JW, Cole CM. Physical and chemical castration of sex offenders. J Off Rehab 1997; 25 (3-4): 1-18
107. Money J. Paraphilia and abuse-martyrdom: exhibitionism as a paradigm for reciprocal couple counseling combined with antiandrogen. J Sex Marital Ther 1981 Summer; 7 (2): 115-23 (Pubitemid 11052645)
108. Meyer 3rd WJ, Cole C, Emory E. Depo provera treatment for sex offending behavior: an evaluation of outcome. Bull Am Acad Psychiatry Law 1992; 20 (3): 249-59
109. Meyer 3rd WJ, Wiener I, Emory LE, et al. Cholelithiasis associated with medroxyprogesterone acetate therapy in men. Res Commun Chem Pathol Pharmacol 1992 Jan; 75 (1): 69-84
110. McConaghy N, Blaszczynski A, Armstrong MS, et al. Re-sistance to treatment of adolescent sex offenders. Arch Sex Behav 1989 Apr; 18 (2): 97-107 (Pubitemid 19116379)
111. Krueger RB, Hembree W, Hill M. Prescription of medroxyprogesterone acetate to a patient with pedophilia, resulting in Cushing's syndrome and adrenal insufficiency. Sex Abuse 2006 Apr; 18 (2): 227-8 (Pubitemid 44327003)
112. Jeffcoate WJ, Matthews RW, Edwards CR, et al. The effect of cyproterone acetate on serum testosterone, LH, FSH and prolactin in male sexual offenders. Clin Endocrinol 1980; 13 (2): 189-95 (Pubitemid 10053585)
113. Neuman F. Pharmacology and potential use of cyproter-one acetate. Horm Metab Res 1977; 9: 1-13
114. Laschet U, Laschet L. Antiandrogen treatment of patho-logically increased and abnormal sexuality in men. Klin Wochenschr 1967 Mar 15; 45 (6): 324-5
115. Laschet U, Laschet L. The results of clinical studies of the suppression of sexuality by anti-androgens (author's translation). J Neurovisc Relat 1971; 0 (0): Suppl. 10: 388-93
116. Cooper AJ, Sandhu S, Losztyn S, et al. A double-blind placebo controlled trial of medroxyprogesterone acetate and cyproterone acetate with seven pedophiles. Can J Psychiatry 1992 Dec; 37 (10): 687-93 (Pubitemid 23043894)
117. Bradford JM, Pawlak A. Double-blind placebo crossover study of cyproterone acetate in the treatment of the paraphilias. Arch Sex Behav 1993 Oct; 22 (5): 383-402 (Pubitemid 23308999)
118. Laschet U,LaschetL. Antiandrogensin the treatmentof sexual deviations of men. J Steroid Biochem 1975 Jun; 6 (6): 821-6
119. Bradford JM, Pawlak A. Effects of cyproterone acetate on sexual arousal patterns of pedophiles. Arch Sex Behav 1993 Dec; 22 (6): 629-41 (Pubitemid 23349876)
120. Davies TS. Cyproterone acetate for male hypersexuality. J Int Med Res 1974; 2 (2): 159-63
121. Guay DR. Drug treatment of paraphilic and nonparaphilic sexual disorders. Clin Ther 2009 Jan; 31 (1): 1-31
122. Belchetz PE, Plant TM, Nakai Y, et al. Hypophysial responses to continuous and intermittent delivery of hypothalamic gonadotropin-releasing hormone. Science 1978 Nov 10; 202 (4368): 631-3 (Pubitemid 9055618)
123. McEvoy G. AHFS drug information. Bethesda, MD: American Society of Health System Pharmacists; 1999
124. Thibaut F, Cordier B, Kuhn JM. Effect of a long-lasting gonadotrophin hormone-releasing hormone agonist in six cases of severe male paraphilia. Acta Psychiatr Scand 1993 Jun; 87 (6): 445-50 (Pubitemid 23186268)
125. Thibaut F, Cordier B, Kuhn JM. Gonadotrophin hormone releasing hormone agonist in cases of severe paraphilia: a lifetime treatment? Psychoneuroendocrinology 1996 May; 21 (4): 411-9 (Pubitemid 26276649)
126. Thibaut F, Kuhn JM, Cordier B, et al. Hormone treatment of sex offenses. Encephale 1998 Mar-Apr; 24 (2): 132-7
127. Hansen H, Lykke-Olesen L. Treatment of dangerous sexual offenders in Denmark. J Forensic Psychiatry 1997; 8: 195-9 (Pubitemid 27232102)
128. Czerny JP, Briken P, Berner W. Antihormonal treatment of paraphilic patients in German forensic psychiatric clinics. Eur Psychiatry 2002 Apr; 17 (2): 104-6 (Pubitemid 34467873)
129. Briken P, Nika E, Berner W. Treatment of paraphilia with luteinizing hormone-releasing hormone agonists. J Sex Marital Ther 2001 Jan-Feb; 27 (1): 45-55 (Pubitemid 32094966)
130. Briken P. Pharmacotherapy of paraphilias with luteinizing hormone-releasing hormone agonists. Arch Gen Psychiatry 2002 May; 59 (5): 469-70; author reply, 70 (Pubitemid 34477686)
131. Krueger RB, Kaplan MS. Depot-leuprolide acetate for treatment of paraphilias: a report of twelve cases. Arch Sex Behav 2001 Aug; 30 (4): 409-22 (Pubitemid 39592019)
132. Schober JM, Kuhn PJ, Kovacs PG, et al. Leuprolide acet-ate suppresses pedophilic urges and arousability. Arch Sex Behav 2005 Dec; 34 (6): 691-705 (Pubitemid 41803666)
133. Schober JM, Byrne PM, Kuhn PJ. Leuprolide acetate is a familiar drug that may modify sex-offender behaviour: the urologist's role. BJU Int 2006 Apr; 97 (4): 684-6 (Pubitemid 43383494)
134. Briken P, Hill A, Berner W. A relapse in pedophilic sex offending and subsequent suicide attempt during lutei-nizing hormone-releasing hormone treatment [letter]. J Clin Psychiatry 2004 Oct; 65 (10): 1429
135. Rousseau L, Couture M, Dupont A, et al. Effect of combined androgen blockade with an LHRH agonist and flutamide in one severe case of male exhibitionism. Can J Psychiatry 1990 May; 35 (4): 338-41 (Pubitemid 20233567)
136. Hoogeveen J, Van der Veer E. Side effects of pharma-cotherapy on bone with long-acting gonadorelin agonist triptorelin for paraphilia. J Sex Med 2008 Mar; 5 (3): 626-30 (Pubitemid 351337889)
137. Grasswick LJ, Bradford JM. Osteoporosis associated with the treatment of paraphilias: a clinical review of seven case reports. J Forensic Sci 2003 Jul; 48 (4): 849-55 (Pubitemid 36801477)
138. McConaghy N. Paedophilia: a review of the evidence. Aust N Z J Psychiatry 1998 Apr; 32 (2): 252-65; discussion 266-7
139. Marshall WL, Ward T, Mann RE, et al. Working positively with sexual offenders: maximizing the effectiveness of treatment. J Interpers Violence 2005 Sep; 20 (9): 1096-114 (Pubitemid 41304888)
140. Ward T, Gannon TA, Birgden A. Human rights and the treatment of sex offenders. Sex Abuse 2007 Sep; 19 (3): 195-216
141. Berlin FS. Sex offender treatment and legislation. J Am Acad Psychiatry Law 2003; 31 (4): 510-3 (Pubitemid 38120795)
142. Belgian Advisory Commitee on Bioethics. Opinion no. 39 of December 18th 2006 on hormonal treatment of sex offenders [online]. Available from URL: http://www. health.belgium.be/eportal/Healthcare/Consultativebodies/ Commitees/Bioethics/Opinions/index.htm [Accessed 2011 Feb 16]
143. Berlin F. Risk/benefit ratio of androgen deprivation treat-ment for sex offenders. J Am Acad Psychiatry Law 2009; 37: 59-62
144. Kahn TJ, Lafond MA. Treatment of the adolescent sexual offender. Child Adolesc Social Work 1988; 5: 135-48
145. Bremer JF. Serious juvenile sex offenders: treatment and long term follow-up. Psychiat Ann 1992; 22: 326-32
146. Worling JR, Curwen T.Adolescent sexual offender recidivism: success of specialized treatment and implications for risk prediction. Child Abuse Negl 2000 Jul; 24 (7): 965-82 (Pubitemid 30320881)
147. Gerardin P, Thibaut F. Epidemiology and treatment of juve-nile sexual offending. Paediatr Drugs 2004; 6 (2): 79-91
148. Reitzel LR, Carbonell JL. The effectiveness of sexual of-fender treatment for juveniles as measured by recidivism: a meta-analysis. Sex Abuse 2006 Oct; 18 (4): 401-21 (Pubitemid 44916426)
149. Cooper AJ. Review of the role of two antilibidinal drugs in the treatment of sex offenders with mental retardation. Ment Retar 1995; 33 (1): 42-8
150. Sherak DL. Pharmacological treatment of sexually offend-ing behavior in people with mental retardation/ developmental disabilities. Ment Health Asp Dev Disabil 2000; 3 (2): 62-74 (Pubitemid 30352666)